The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
The authors developed and validated the Watts Connectedness Scale (WCS), a three‑dimensional measure of felt connectedness to self, others and the wider world that demonstrated a stable factor structure and good internal consistency. WCS scores rose significantly after psychedelic experiences—correlating with mystical, emotional‑breakthrough and communitas measures—and increased more after psilocybin therapy than escitalopram in a randomised controlled trial, indicating sensitivity to therapeutically relevant change.
Authors
- Robin Carhart-Harris
- David Nutt
- Christopher Timmermann
Published
Abstract
Rationale
A general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connectedness to self, others and the wider world have been reported by participants in clinical trials of psychedelic therapy. Such accounts have led us to a definition of the psychological construct of ‘connectedness’ as ‘a state of feeling connected to self, others and the wider world’. Existing tools for measuring connectedness have focused on particular aspects of connectedness, such as ‘social connectedness’ or ‘nature connectedness’, which we hypothesise to be different expressions of a common factor of connectedness. Here, we sought to develop a new scale to measure connectedness as a construct with these multiple domains. We hypothesised that (1) our scale would measure three separable subscale factors pertaining to a felt connection to ‘self’, ‘others’ and ‘world’ and (2) improvements in total and subscale WCS scores would correlate with improved mental health outcomes post psychedelic use.
Objectives
To validate and test the ‘Watts Connectedness Scale’ (WCS).
Methods
Psychometric validation of the WCS was carried out using data from three independent studies. Firstly, we pooled data from two prospective observational online survey studies. The WCS was completed before and after a planned psychedelic experience. The total sample of completers from the online surveys wasN = 1226. Exploratory and confirmatory factor analysis were performed, and construct and criterion validity were tested. A third dataset was derived from a double-blind randomised controlled trial (RCT) comparing psilocybin-assisted therapy (n = 27) with 6 weeks of daily escitalopram (n = 25) for major depressive disorder (MDD), where the WCS was completed at baseline and at a 6-week primary endpoint.
Results
As hypothesised, factor analysis of all WCS items revealed three main factors with good internal consistency. WCS showed good construct validity. Significant post-psychedelic increases were observed for total connectedness scores (η2 = 0.339,p < 0.0001), as well as on each of its subscales (p < 0.0001). Acute measures of ‘mystical experience’, ‘emotional breakthrough’, and ‘communitas’ correlated positively with post-psychedelic changes in connectedness (r = 0.42,r = 0.38,r = 0.42, respectively,p < 0.0001). In the RCT, psilocybin therapy was associated with greater increases in WCS scores compared with the escitalopram arm (ηp2 = 0.133, p = 0.009).
Conclusions
The WCS is a new 3-dimensional index of felt connectedness that may sensitively measure therapeutically relevant psychological changes post-psychedelic use. We believe that the operational definition of connectedness captured by the WCS may have broad relevance in mental health research.
Research Summary of 'The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world'
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Watts, R., Kettner, H., Geerts, D., Gandy, S., Kartner, L., Mertens, L., Timmermann, C., Nour, M. M., Kaelen, M., Nutt, D., Carhart-Harris, R., & Roseman, L. (2022). The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. Psychopharmacology, 239(11), 3461-3483. https://doi.org/10.1007/s00213-022-06187-5
References (34)
Papers cited by this study that are also in Blossom
Agin-Liebes, G. I., Ekman, E., Anderson, B. T. et al. · Journal of Humanistic Psychology (2021)
Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)
Argento, E., Capler, R., Thomas, G. et al. · Drug and Alcohol Review (2019)
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Davis, A. K., Clifton, J. M., Weaver, E. G. et al. · Journal of Psychopharmacology (2020)
Show all 34 referencesShow fewer
Forstmann, M., Sagioglou, C. · Journal of Psychopharmacology (2017)
Forstmann, M., Yudkin, D. A., Prosser, A. M. B. et al. · PNAS (2020)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Kuc, J., Kettner, H., Rosas, F. E. et al. · Psychopharmacology (2021)
Loizaga-Velder, A., Verres, R. · Journal of Psychoactive Drugs (2014)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Schenberg, E. E. · Frontiers in Pharmacology (2018)
Siegel, A. N., Lipsitz, O., Gill, H. et al. · Journal of Psychiatric Research (2021)
Spriggs, M. J., Kettner, •. H., Carhart-Harris, •. R. L. · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity (2020)
Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)
Timmermann, C., Kettner, H., Letheby, C. et al. · Scientific Reports (2021)
Trichter, S., Klimo, J., Krippner, S. · Journal of Psychoactive Drugs (2009)
Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Zeifman, R. J., Wagner, A. C., Watts, R. et al. · Frontiers in Psychiatry (2020)
Cited By (26)
Papers in Blossom that reference this study
Goldy, S. P., Sepeda, N. D., Hilbert, S. N. et al. · Psychiatry Research (2026)
Meikle, S., Carter, O., Liknaitzky, P. et al. · Therapeutic Advances in Psychopharmacology (2025)
Knock, E., Siefried, K. J., Gill Bedi, |. et al. · Addiction (2025)
Roseby, W., Kettner, H., Roseman, L. et al. · Frontiers in Psychology (2025)
Wall, M. B., Demetriou, L., Giribaldi, B. et al. · American Journal of Psychiatry (2025)
Harding, R., Singer, N., Wall, M. B. et al. · Molecular Psychiatry (2025)
Ruban, A., Magnuski, M., Hobot, J. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025)
Lewis, B. R., Hendrick, J., Byrne, K. et al. · PLOS Medicine (2025)
Erritzoe, D., Barba, T., Greenway, K. T. et al. · EClinicalMedicine (2024)
Yaden, D. B., Goldy, S. P., Weiss, B. et al. · Nature Reviews Psychology (2024)
Show all 26 papersShow fewer
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · Biological Psychiatry (2024)
Sloshower, J. A., Zeifman, R. J., Guss, J. et al. · Scientific Reports (2024)
Peill, J. M., Marguilho, M., Erritzoe, D. et al. · Journal of Psychopharmacology (2024)
Barba, T., Kettne, H., Radu, C. et al. · Scientific Reports (2024)
Beaussant, Y., Tarbi, E., Nigam, K. B. et al. · Cancer (2023)
Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)
Jacobs, E., Murphy-Beiner, A., Rouiller, I. et al. · Neuroethics (2023)
Molla, H. M., Lee, R., Lyubomirsky, S. et al. · Scientific Reports (2023)
Heinzerling, K. G., Sergi, K., Linton, M. et al. · Frontiers in Psychiatry (2023)
Zeifman, R. J., Kettner, H., Pagni, B. A. et al. · Scientific Reports (2023)
Zeifman, R. J., Wagner, A. C., Monson, C. M. et al. · Journal of Affective Disorders (2023)
Weiss, B., Wingert, A., Erritzoe, D. et al. · Scientific Reports (2023)
Luke, D., Gandy, S., Irvine, A. et al. · Psychoactives (2023)
Boehnke, K. F., Kruger, D. J., Lucas, P. · International Journal of Mental Health and Addiction (2023)
Sjöstedt-Hughes, P. · Frontiers in Psychology (2023)
Kałużna, A., Schlosser, M., Gulliksen Craste, E. et al. · Journal of Psychedelic Studies (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.